Sangamo Therapeutics, Inc.
SGMO
$0.4831
-$0.0169-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -14.75% | -84.72% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -14.75% | -84.72% | |||
| Cost of Revenue | 9.84% | -14.63% | |||
| Gross Profit | -21.36% | -174.37% | |||
| SG&A Expenses | 3.00% | 12.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.84% | -8.08% | |||
| Operating Income | -14.43% | -298.68% | |||
| Income Before Tax | -27.94% | -321.40% | |||
| Income Tax Expenses | 127.87% | -585.23% | |||
| Earnings from Continuing Operations | -30.78% | -319.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.78% | -319.23% | |||
| EBIT | -14.43% | -298.68% | |||
| EBITDA | -16.06% | -272.99% | |||
| EPS Basic | -24.80% | -347.33% | |||
| Normalized Basic EPS | -19.64% | -283.04% | |||
| EPS Diluted | -19.84% | -389.75% | |||
| Normalized Diluted EPS | -19.64% | -288.28% | |||
| Average Basic Shares Outstanding | 4.80% | 0.88% | |||
| Average Diluted Shares Outstanding | 4.80% | -1.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||